Company: BIAF
Filing Date: 2025-05-23
Form Type: PRER14A
Source: 0001641172-25-012315
Chunk: 88

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-05-23
Form: PRER14A
Chunk 88
---
'>FOR ☐AGAINST ☐ABSTAIN ☐</div>

| 5. | Proposal                                                                                                                     
 to approve an amendment to the Company’s Certificate of Incorporation, as amended, in substantially the form attached to the 
 accompanying proxy statement as Appendix B, at the discretion of the Board, to increase the authorized number of shares of   
 the Company’s Common Stock, from 100,000,000 to 350,000,000 (the “Authorized Increase Proposal”);                            |

<div align='center'>FOR ☐AGAINST ☐ABSTAIN ☐</div>

| 6. | Proposal                                                                                         
 to approve an anti-dilution provision of the Common Stock purchase warrants issued in connection 
 with our public offering that closed on May 7, 2025 (the “May 2025 Warrants”),                   
 and the reduction in exercise price of the May 2025 Warrants (subject to a floor price of        
 $0.10 per share) and corresponding increase in the number of shares issuable upon exercise       
 thereof of up to an aggregate maximum of 49,907,811 shares of our Common Stock, resulting        
 from the triggering of such anti-dilution provision (the “Anti-Dilution Adjustment               
 Proposal”).                                                                                      |

<div align='center'>FOR ☐AGAINST ☐ABSTAIN ☐</div>

| 7. | Proposal                                                                                                                                  
 to consider and approve an adjournment of the Annual Meeting to a later date, if necessary or appropriate, to permit further solicitation 
 and vote of proxies in the event that there are insufficient votes for, or otherwise in connection with, the approval of the Reverse      
 Stock Split Proposal, the Warrant Exercise Proposal, the Authorized Increase Proposal and/or the Anti-Dilution Adjustment                 
 Proposal (the “Adjournment Proposal”).                                                                                                    |

<div align='center'>FOR ☐AGAINST ☐ABSTAIN ☐</div>

| In their discretion, the Proxies are authorized                                                                                                                   
 to vote upon such other matters as may properly come before the meeting or any adjournment thereof. Any of the Proxies, or their respective                       
 substitutes, who shall be present and acting at the Annual Meeting shall have and may exercise all the powers hereby granted.                                     |
| The undersigned acknowledges receipt of our 2024 Annual Report to Stockholders, Notice of Annual Meeting of Stockholders and the Proxy Statement related thereto. |
| Please sign exactly as your name(s) appear(s)